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ABSTRACT  
Adult-onset IgA vasculitis or Henoch-Schönlein purpura (HSP) is a systemic vasculitis characterized by IgA1-dominant deposits.  The symptoms 
include cutaneous purpura, ankle arthritis, enteritis and nephritis.  HSP nephritis (HSPN) can be severe and refractory to corticosteroids 
with/without immunosuppressive agents.  The concept of depletion of antibody producing B cell with Rituximab is appealing des pite the 
uncertainity of HSP pathogenesis.  In the present case report; we describe our experience with Rituximab treatment in a patient with this 
disease.  Our patient had different triggering factors for her relapses and lately Rituximab itself.  Review of the literature indicates that 
autoantibodies to Gd-IgA1 did not decrease with Rituximab therapy and others indicated an inherited predisposition for higher levels in 
patients with progressive disease.  Our findings confirm the limited role and risky profile of Rituximab in treatment of HSP.   
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INTRODUCTION 
Adult-onset IgA vasculitis or Henoch-Schönlein purpura 
(HSP) is a systemic vasculitis characterized by IgA1-
dominant deposits [1].  The symptoms include cutaneous 
purpura, ankle arthritis, enteritis and nephritis [2].  Contrary 
to children the disease is rare and is characterized by 
frequent and prolonged relapses as well as progressive 
nephritis [3].  HSP nephritis (HSPN) can be severe and 
refractory to corticosteroids with/without 
immunosuppressive agents [4].  The role of B cells in HSPN is 
not clearly defined with few case reports and studies 
showing high rates of remission and preservation of 
glomerular function with Rituximab therapy [5, 6].  The 
concept of depletion of antibody producing B cell with 
Rituximab is appealing despite the uncertainty of HSP 
pathogenesis.  In the present case report; we describe our 
experience with Rituximab treatment in a patient with this 
disease.   
THE CASE: 
A 30-year-woman presented with purpuric skin rash at 
lower extremities and buttocks.  She also had ankle arthritis, 
abdominal pain and abnormal urine analysis.  The latter 
showed microscopic hematuria and proteinuria (2 g/day).  
Systemic examination did not show abnormality.  Serum 
sugar, urea, creatinine, electrolytes and liver functions were 
normal.  Serum complements (C3 & C4), IgA level and 
protein electrophoresis were normal.  ANA, anti-ds DNA, 
ANCA, anti-GBM-antibodies, RA, hepatitis B surface antigen 
and anti-HCV antibodies were negative.  Kidney biopsy 
showed focal proliferative glomerulonephritis with 
immunoflourescent stains positive only for IgA and C3 in the 
mesangium (Fig. 1A).  Since she had severe abdominal pain 
and ankle arthritis; she had received Prednisone 20 mg/day, 
for 2 weeks, and felt better.  For her proteinuria; she 
received Lisinopril 20 mg/day and it decreased to < 500 
mg/day.  Two years later, she presented with the severe 
abdominal pains and the purpuric rash reappeared.  She was 
pregnant at 12 weeks.  At that time, her blood tests, liver and 
renal functions were normal except for hematuria and 
proteinuria again.  She had discontinued Lisinopril months 
ago and planned for her current pregnancy.  Upon 
assessment, her fetus was dead and evacuation was done.  
However, in next few days she did not improve, even with 
high-dose Corticosteroids, and her rash became worse.  She 
was re-evaluated by her gynecologist and found to have 
placental remnants.  After proper evacuation, she felt better 
and the rash disappeared.  Subsequently, she lost follow up 
and presented for management during 2 more successful 
pregnancies without complications except for increment of 
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her proteinuria to 3 g/day and decrease creatinine clearance 
to 50 ml/minute.  In an attempt to improve her IgA disease, 
Rituximab was tried at a dose of 1 g to be followed by 
another 1 g 2 weeks later.  However, after the first Rituximab 
infusion, she developed the purpuric rash again (Fig. 2).  Skin 
biopsy showed non-necrotizing subepidermal 
leucocytoclastic vasculitis (Fig. 3).  Moreover, she had 
abdominal pain, ankle arthritis and serum creatinine had 
increased from normal to 250 umol/L.  Biopsy of the skin 
rash showed leukocytoclastic vasculitis (Fig. 3).  Kidney 
biopsy; showed focal proliferative glomerulonephritis with 
IgA deposits yet with cellular crescent formation > 50% (Fig. 
1B).  She was treated with Solumedrol 1 g daily for 3 days 
followed by Prednisone 60 mg/day for 1 month.  The latter 
was tapered down and was discontinued 2 more months 
later.  She felt better and her serum creatinine decreased to 
165 umol/L.  Repeat kidney biopsy 6 months later showed 
that 60% of her glomeruli have global sclerosis with fibrous 
crescents and mesangial fibrosis (Fig. 1C).  In the past 2 
years; she is being treated with Lisinopril 20 mg daily with 
Spironolactone 25 mg twice weekly.  Moreover, she was 
instructed to avoid further pregnancies.   She did not have 
subsequent relapse and her creatinine clearance is 30 
ml/minute with proteinuria at 800 mg/day. 
     
 
Figure 1. Photomicrograph of kidney biopsy: (A) initially showing just segmental mesangioprolifertion.  (B) Immediately after 
Rituximab therapy showing extensive cellular crescents.  (C) 6 months after Rituximab therapy.  H&E X 100 
 
Figure 2.  Showing extensive purpura after Rituximab therapy. 
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Figure 3.  Photomicrograph of skin showing a subepidermal vessel surrounded by neutrophils and lymphocytes without 
destruction (necrosis) of its wall.  Note, its endothelial swelling and red cells leak (diapedesis) responsible for purpura. H&E 
X100  
 
DISCUSSION 
Patients with HSP have an underlying IgA disease with 
persistent hematuria [7].  The prognosis of HSP depends on: 
(a) frequency of relapses of the systemic disease and (b) 
outcome of its nephritis [8].  Hence, management of HSPN 
entails: (a) control of relapses and (b) prevention of its 
progressive IgA disease.  The triggering factors for relapses 
are difficult to ascertain yet infections and drugs are 
common culprits.  Moreover, relapses are usually associated 
with crescent formation on top of a focal proliferative IgA 
disease [9].  Naturally; frequent and poorly-treated relapses 
has poor prognosis since associated progressive crescentic 
glomerular loss as seen in our patient.  Our patient 
experienced her first relapse with intra-uterine fetal death 
then concealed placental remnants.  The second relapse was 
timely related to Rituximab therapy.  The latter was used to 
slow the progression of her chronic IgAN yet was 
immunogenic.  Unless contraindicated by infections; 
Corticosteroids and immunosuppressive agents are indicated 
in crescentic IgAN [10].  On the other hands; halting the 
progression of the chronic disease i.e. IgAN should be include 
safe and efficacious measures.  Unfortunately, Rituximab-use 
in such prophylaxis was not safe and had induced a relapse 
of HSPN.  Recent large randomized multicenter trials 
questioned the role of Corticosteroids, immunosuppression 
and even Rituximab in halting the progression of chronic 
IgAN [11].  Interestingly, IgAN is the most common primary 
glomerular disease in the world [12].  Among patients with 
reduced renal function and proteinuria >1 g/24 h, outcomes 
remain poor with up to 50% of such patients can progress to 
ESRD over 10 years [13].   The concept of an underlying 
immunological disorder stemmed from the discovery of 
galactose deficient-IgA1 phenomenon.  The extent of 
Mesangial Gd-IgA1 deposition and its serum levels was 
associated with disease progression [14, 15].   However, in a 
recent multicentric study; there was no favorable effect of 
rituximab on the level of Gd-IgA1 [16].  Moreover, a recent 
study questioned the role of autoimmunity in the 
development of aggressive disease in IgAN and indicated that 
a higher level of Gd-IgA1 is a hereditary predisposition [17].  
Our findings indicate that Rituximab is not useful in IgAN and 
can trigger flare of HSP with further crescent formation and 
progressive disease.   At present, the established benefit in 
halting the progressive nature of IgAN in predisposed 
patients with high autoantibodies to Gd-IgA1 is limited to 
decrease intraglomerular pressure via: (a) limiting 
pregnancies in females and (b) agents that antagonize the 
renin-angiotensin-aldosterone system (RAAS) [18]. 
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